Literature DB >> 3455629

Radioimmunoassay for osteonectin. Concentrations in bone, nonmineralized tissues, and blood.

L Malaval1, B Fournier, P D Delmas.   

Abstract

We describe a double antibody radioimmunoassay for the bone protein osteonectin using a polyclonal antibody raised against bovine fetal bone osteonectin. This assay, which cross-reacts with human osteonectin, was used to explore the tissue distribution of the protein. Osteonectin was detected in extracts of nonmineralized tissues from bovine fetuses, with concentrations ranging from 10 ng/100 micrograms of proteins in the lens to about 80 ng/100 micrograms in collagen-rich tissues (e.g., tendon), which represents respectively from 0.01% to 0.5% of the concentrations found in bone extracts. Osteonectin is thus a widespread component of extracellular matrix, although its concentration is minute in tissues other than bone and dentin. Adult human serum contains 200 ng/ml of osteonectin and values obtained in plasma prepared without platelet activation are about one-third of those in matched sera. This platelet-independent fraction might be used as a marker for bone metabolism.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3455629     DOI: 10.1002/jbmr.5650020514

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  5 in total

1.  Osteonectin (SPARC) expression in human liver and in cultured human liver myofibroblasts.

Authors:  S Blazejewski; B Le Bail; L Boussarie; J F Blanc; L Malaval; K Okubo; J Saric; P Bioulac-Sage; J Rosenbaum
Journal:  Am J Pathol       Date:  1997-09       Impact factor: 4.307

2.  A monoclonal antibody against dentin phosphophoryn recognizes a bone protein(s) appearing at the beginning of ossification.

Authors:  T Nakama; O Nakamura; Y Daikuhara; T Semba
Journal:  Calcif Tissue Int       Date:  1988-10       Impact factor: 4.333

3.  Expression of SPARC during development of the chicken chorioallantoic membrane: evidence for regulated proteolysis in vivo.

Authors:  M L Iruela-Arispe; T F Lane; D Redmond; M Reilly; R P Bolender; T J Kavanagh; E H Sage
Journal:  Mol Biol Cell       Date:  1995-03       Impact factor: 4.138

4.  Bone matrix osteonectin limits prostate cancer cell growth and survival.

Authors:  Kristina Kapinas; Katie M Lowther; Catherine B Kessler; Karissa Tilbury; Jay R Lieberman; Jennifer S Tirnauer; Paul Campagnola; Anne M Delany
Journal:  Matrix Biol       Date:  2012-04-16       Impact factor: 11.583

5.  SPARC expression by cerebral microvascular endothelial cells in vitro and its influence on blood-brain barrier properties.

Authors:  Samir Alkabie; Jayasree Basivireddy; Lixin Zhou; Jane Roskams; Peter Rieckmann; Jacqueline A Quandt
Journal:  J Neuroinflammation       Date:  2016-08-31       Impact factor: 8.322

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.